SEC Filings
Cabaletta Bio’s Rese-cel Keeps All 6 Dermatomyositis Patients Improving At One Year
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
Earnings
Operating earnings fell to $12,705 million in the third quarter, while Berkshire spent approximately $9.6 billion buying back shares.
SEC Filings
Frontage operations would broaden its human-trial testing business, with up to $75 million more payable based on performance.
SEC Filings
The company expects to submit the report within five calendar days while management finishes assembling and checking information.
SEC Filings
The planned purchase adds peptide drug discovery to argenx’s antibody business, with potential oral and long-acting treatments.
SEC Filings
Clal holds 85,519 shares for its own account; subsidiaries independently manage the shares held for public clients.
Earnings
Recast comparisons show a third-quarter decline, while capital inflows fell 33% from a year earlier.
SEC Filings
The drug developer’s most advanced candidate is in late-stage testing for relapsing multiple sclerosis.
SEC Filings
The company denies wrongdoing as holders prepare to vote on its proposed acquisition by onsemi on November 17.
SEC Filings
The board backs the proposal unanimously, while broker-held shareholders face a warning about relying on earlier voting instructions.
Insider Trades
Barrocas still holds 1,565,453 shares, valued at approximately $349 million at Friday's close.
SEC Filings
The ownership update changes entity names and retains agreements to support Tungsten OpCo Holder’s board nominees.